Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.

Journal Article (Journal Article)

Aim: To evaluate real-world clinical outcomes of radium-223 or alternative novel hormonal therapy (NHT) following first-line NHT for metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: Retrospective analysis of the US Flatiron database (ClinicalTrials.gov identifier: NCT03896984). Results: In the radium-223 cohort (n = 120) versus the alternative NHT cohort (n = 226), proportionally more patients had prior symptomatic skeletal events and bone-only metastases, and first-line NHT duration was shorter. Following second-line therapy, 49 versus 39% of patients received subsequent life-prolonging therapy; of these, 47 versus 76% received taxane. Median overall survival was 10.8 versus 11.2 months. Conclusion: Real-world patients with mCRPC had similar median overall survival following second-line radium-223 or alternative NHT after first-line NHT. Many patients received subsequent therapy, with less taxane use after radium-223.

Full Text

Duke Authors

Cited Authors

  • Sartor, O; George, D; Tombal, B; Agarwal, N; Higano, CS; Sternberg, CN; Miller, K; Jiao, X; Guo, H; Sandström, P; Bruno, A; Verholen, F; Saad, F; Shore, N

Published Date

  • January 2022

Published In

Volume / Issue

  • 18 / 1

Start / End Page

  • 35 - 45

PubMed ID

  • 34636627

Electronic International Standard Serial Number (EISSN)

  • 1744-8301

Digital Object Identifier (DOI)

  • 10.2217/fon-2021-0886

Language

  • eng

Conference Location

  • England